Capital Infusion. The Company will support PSI’s financial needs beginning on the Closing Date and going forward on an as needed basis.
Capital Infusion. On or prior to the Effective Date, the Management Shareholders, shall (a) invest $3,000,000 (the “Initial Capital Infusion”) in the New Guarantor in exchange for the issuance of Preferred Equity issued separately and apart from the Rights Offering, (b) unconditionally backstop the funding of an additional investment of $7,000,000 (the “Final Capital Infusion”, and together with the Initial Capital Infusion, the “Capital Infusion”) in the New Guarantor by depositing the Final Capital Infusion in an escrow account with JPMorgan Chase Bank, National Association in accordance with the Escrow Agreement; and (c) execute and deliver the Investment Agreement and the Escrow Agreement, each in form and substance reasonably satisfactory to the Lender. Pursuant to the Investment Agreement, the New Guarantor shall issue to the Management Shareholders and other shareholders rights, in exchange for the Capital Infusion, rights to acquire preferred stock, convertible preferred stock or similar equity securities in the New Guarantor (the “Preferred Equity”). The proceeds of any Capital Infusion up to Twenty million Dollars ($20,000,000) shall be deposited in one or more segregated accounts held by the New Guarantor for the purposes permitted by the Loan Agreement (the “Special Account”).
Capital Infusion. Notwithstanding anything to the contrary contained herein or in the Loan Agreement:
(a) Borrower may elect to use Borrowing Base Option AA until the earlier of (i) May 30, 2008, (ii) the date on which Borrower consummates the Capital Infusion or (iii) the date Borrower is notified that its partners and/or management will not provide the Capital Infusion.
(b) Borrower may elect to use Borrowing Base Option C solely following the consummation of the Capital Infusion so long as Borrower consummates the Capital Infusion on or before May 30, 2008.
(c) Borrower shall deliver to Bank any and all documents, instruments and agreements evidencing and/or relating to the Capital Infusion at least two (2) Business Days prior to the consummation of the Capital Infusion and the form, substance and terms thereof shall acceptable to Bank in its sole and absolute discretion.
(d) Prior to the consummation of the Capital Infusion, Borrower and Latitude shall have executed and delivered to Bank an amended and restated Licensor Agreement, in form and substance acceptable to Bank.
Capital Infusion. 7 2.4 SLAs..................................................................... 8 2.5 Sole Provider of Services................................................ 9 2.6
Capital Infusion. Based on the State's long-term commitment to Provider, Provider will fund investments in the State's infrastructure in connection with the Services. Such investments are listed in the Pricing Matrices in Schedule B. Except as otherwise provided in this Agreement, all such investments shall, for purposes of the State's rights upon Disentanglement, pursuant to Section 16, be capitalized, accounted for, and depreciated by Provider, without regard to the actual method of acquisition (i.e., whether by purchase, lease, or other method of financing).
Capital Infusion. The Company will support NPC’s financial needs beginning on the Closing Date and going forward on an as needed basis.
Capital Infusion. MEDMarket acknowledges that Netivation has provide it with Twenty Thousand Dollars ($20,000) for working capital purposes.
Capital Infusion. No later than December 31, 2016, Borrower shall have received an infusion of equity, or subordinated debt securities convertible into equity, for aggregate proceeds equal to no less than Two Hundred Thousand Dollars ($200,000) in form and substance satisfactory to Lender in its sole and absolute discretion.
Capital Infusion. As additional consideration for the purchase and sale of the Company shares, the Company shall repay the Capital Infusion to the Parent. The Company shall repay the Capital Infusion by delivering to the Parent a promissory note (the “Reversal Note”) in the principal amount of Five Hundred Fifty Seven Thousand Nine Hundred Twenty Seven Dollars and Thirty Cents ($557,927.
Capital Infusion. As part of the Executive's responsibilities hereunder, the Executive will study the advisability of the Company divesting its CATV business, and will make a recommendation to the Board with respect thereto. In the event that the Company determines to retain this business, the Executive, or an investor group designated by Executive, will purchase common stock from the Company for an aggregate cash purchase price of $500,000. Such stock will be issued and sold to the Executive at a per share price equal to the stock's then market price.
